FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W289405924> ?p ?o ?g. }

• W289405924 endingPage "72" @default.
• W289405924 startingPage "265" @default.
• W289405924 abstract "Immunological parameters were studied in patients with either advanced renal cell cancer (n = 7) or advanced malignant melanoma (n = 6) during treatment with a low-dose continuous intravenous treatment with human recombinant interleukin-2 (hr IL-2) and recombinant interferon alpha-2a. Before treatment, natural killer (NK) cell activity was found to be significantly lower in these patients than in 10 normal controls. However, the numbers of NK cells in circulation were equivalent; following incubation of the patients' peripheral blood mononuclear cells (PBMC) with IL-2 for three days normal lymphokine activated killer (LAK) cell activities were induced. Thus, in-vitro incubation with IL-2 appeared to overcome a defect in NK activity. We next examined the effect of IL-2/IFN alpha therapy on in-vitro LAK induction. Treatment significantly increased in-vitro LAK activity in eight of nine patients tested, although in-vivo LAK cell activity was not altered during treatment. The numbers of NK cells (CD16+ CD56+) in peripheral blood showed a significant increase in seven of ten patients as a result of treatment. The three patients who showed the best clinical response also showed the highest increase in expression of these phenotypic markers. T cells were found to be activated in 8/10 patients as indicated by increased co-expression of CD3 with CD25 after completion of 4-day continuous intravenous infusion of IL2. Four days before the start of treatment, cancer patient PBMC stimulated with concanavalin A (con A) produced significantly greater amounts of TNF compared to normal controls. In-vitro inducible TNF was found to decrease following treatment. Since IL-2 production and lymphocyte proliferation in response to Con A were normal in the patient group and were not altered by treatment, the reduction in TNF levels seemed not to be a general inhibitory effect. Further study of these and other changes in the immune system during IL-2/IFN alpha treatment may help to understand how these immunoregulators cause tumour destruction and to predict their usefulness in individual patients." @default.
• W289405924 created "2016-06-24" @default.
• W289405924 creator A5010477256 @default.
• W289405924 creator A5013189412 @default.
• W289405924 creator A5014880183 @default.
• W289405924 creator A5019937368 @default.
• W289405924 creator A5026940007 @default.
• W289405924 creator A5034408281 @default.
• W289405924 creator A5054767876 @default.
• W289405924 creator A5066134513 @default.
• W289405924 date "1993-06-01" @default.
• W289405924 modified "2023-09-27" @default.
• W289405924 title "Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma." @default.
• W289405924 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8314385" @default.
• W289405924 hasPublicationYear "1993" @default.
• W289405924 type Work @default.
• W289405924 sameAs 289405924 @default.
• W289405924 citedByCount "6" @default.
• W289405924 countsByYear W2894059242016 @default.
• W289405924 crossrefType "journal-article" @default.
• W289405924 hasAuthorship W289405924A5010477256 @default.
• W289405924 hasAuthorship W289405924A5013189412 @default.
• W289405924 hasAuthorship W289405924A5014880183 @default.
• W289405924 hasAuthorship W289405924A5019937368 @default.
• W289405924 hasAuthorship W289405924A5026940007 @default.
• W289405924 hasAuthorship W289405924A5034408281 @default.
• W289405924 hasAuthorship W289405924A5054767876 @default.
• W289405924 hasAuthorship W289405924A5066134513 @default.
• W289405924 hasConcept C114684123 @default.
• W289405924 hasConcept C126322002 @default.
• W289405924 hasConcept C129374314 @default.
• W289405924 hasConcept C137061746 @default.
• W289405924 hasConcept C150903083 @default.
• W289405924 hasConcept C167672396 @default.
• W289405924 hasConcept C202751555 @default.
• W289405924 hasConcept C203014093 @default.
• W289405924 hasConcept C207001950 @default.
• W289405924 hasConcept C2776090121 @default.
• W289405924 hasConcept C2776178377 @default.
• W289405924 hasConcept C2777371288 @default.
• W289405924 hasConcept C2777472916 @default.
• W289405924 hasConcept C2777658100 @default.
• W289405924 hasConcept C2777701055 @default.
• W289405924 hasConcept C2777761686 @default.
• W289405924 hasConcept C2778690821 @default.
• W289405924 hasConcept C2781462264 @default.
• W289405924 hasConcept C28651165 @default.
• W289405924 hasConcept C2908885563 @default.
• W289405924 hasConcept C49382859 @default.
• W289405924 hasConcept C502942594 @default.
• W289405924 hasConcept C55493867 @default.
• W289405924 hasConcept C71924100 @default.
• W289405924 hasConcept C79484868 @default.
• W289405924 hasConcept C86803240 @default.
• W289405924 hasConcept C8891405 @default.
• W289405924 hasConceptScore W289405924C114684123 @default.
• W289405924 hasConceptScore W289405924C126322002 @default.
• W289405924 hasConceptScore W289405924C129374314 @default.
• W289405924 hasConceptScore W289405924C137061746 @default.
• W289405924 hasConceptScore W289405924C150903083 @default.
• W289405924 hasConceptScore W289405924C167672396 @default.
• W289405924 hasConceptScore W289405924C202751555 @default.
• W289405924 hasConceptScore W289405924C203014093 @default.
• W289405924 hasConceptScore W289405924C207001950 @default.
• W289405924 hasConceptScore W289405924C2776090121 @default.
• W289405924 hasConceptScore W289405924C2776178377 @default.
• W289405924 hasConceptScore W289405924C2777371288 @default.
• W289405924 hasConceptScore W289405924C2777472916 @default.
• W289405924 hasConceptScore W289405924C2777658100 @default.
• W289405924 hasConceptScore W289405924C2777701055 @default.
• W289405924 hasConceptScore W289405924C2777761686 @default.
• W289405924 hasConceptScore W289405924C2778690821 @default.
• W289405924 hasConceptScore W289405924C2781462264 @default.
• W289405924 hasConceptScore W289405924C28651165 @default.
• W289405924 hasConceptScore W289405924C2908885563 @default.
• W289405924 hasConceptScore W289405924C49382859 @default.
• W289405924 hasConceptScore W289405924C502942594 @default.
• W289405924 hasConceptScore W289405924C55493867 @default.
• W289405924 hasConceptScore W289405924C71924100 @default.
• W289405924 hasConceptScore W289405924C79484868 @default.
• W289405924 hasConceptScore W289405924C86803240 @default.
• W289405924 hasConceptScore W289405924C8891405 @default.
• W289405924 hasIssue "3" @default.
• W289405924 hasLocation W2894059241 @default.
• W289405924 hasOpenAccess W289405924 @default.
• W289405924 hasPrimaryLocation W2894059241 @default.
• W289405924 hasRelatedWork W1568103831 @default.
• W289405924 hasRelatedWork W1979896738 @default.
• W289405924 hasRelatedWork W1999186358 @default.
• W289405924 hasRelatedWork W2049598511 @default.
• W289405924 hasRelatedWork W2060291012 @default.
• W289405924 hasRelatedWork W2069332936 @default.
• W289405924 hasRelatedWork W2093774998 @default.
• W289405924 hasRelatedWork W2131683379 @default.
• W289405924 hasRelatedWork W2416963389 @default.
• W289405924 hasRelatedWork W289405924 @default.
• W289405924 hasVolume "19" @default.
• W289405924 isParatext "false" @default.

• next